PHANTASTIC
Research type
Research Study
Full title
A comparison of plerixafor/G-CSF with chemotherapy/G-CSF for stem cell transplantation
IRAS ID
26514
Contact name
Richard Clark
Contact email
Sponsor organisation
Royal Liverpool and Broadgreen University Hospitals
Eudract number
2009-013798-16
Research summary
High doses of chemotherapy are of benefit in some patients with lymphoma or myeloma, but this can be toxic to the bone marrow. This is minimised by harvesting marrow 'stem' cells from the blood stream before chemotherapy, which are then transplanted back shortly after completing the chemotherapy; this is known as an autograft. Existing methods for mobilising and collecting stem cells require substantial doses of chemotherapy, take up to 2 weeks, do not always work, and may be toxic for some patients. Plerixafor is a new non-chemotherapy drug that works by detaching stem cells from their moorings in the marrow, allowing them to float into the bloodstream. Earlier studies have shown that plerixafor can mobilise adequate stem cell numbers with minimal toxicity within a week in most patients. In this pilot study, we will investigate whether plerixafor is at least as good as chemotherapy for collecting stem cells from the blood. Sixty patients with either myeloma or lymphoma who require autografts will be studies over approximately 2 years, and the findings compared with 120 similar patients from whom we have already collected stem cells.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
09/H1005/60
Date of REC Opinion
1 Feb 2010
REC opinion
Further Information Favourable Opinion